Nimotuzumab Asian Scientific Meeting 2015

Honorary ChairmenSun Yan, Xu Guozhen, Guan

Zhongzhen
20th June, Morning (8:30-12:30)
ChairmenDr Tania Crombet-RamosXu RuihuaShi
Yuankai
1. Nimotuzumab Global Clinical Development Program.
Dr Normando E. Iznaga-Escobar, Chief Scientific Officer,
InnoCIMAb Pte Ltd, Singapore.
2. Role of EGFR on cancer immunotherapy.
Dr Tania Crombet-Ramos, Clinical Director, Center of Molecular
Immunology, Havana, Cuba.
3. Nimotuzumab plus chemotherapy versus chemotherapy alone in
advanced non-small- cell lung cancer: a multicenter, randomized
open-label Phase II study
Dr Ashok Vaid, Medanta Medicity ,Gurgaon, Haryana, India
4. Nimotuzumab on the Treatment of malignant tumor with brain
metastases
Sun Tao, Liaoning Provincial Tumour Hospital, China.
5. Use of nimotuzumab on the treatment of cancer: role of
maintenance therapy and chronicity of the treatment.
Dr Mayra Ramos-Suzarte, Clinical Manager, Biotech
Pharmaceutical Co. Ltd. , Beijing, China.
Discussion: Pan Hongming
The Discussant: Dr Ravi ThippeswamyDr Neelesh ReddyDr
Krishna PrasadBai ChunmeiHu YiWei QichunWang Xin.

Nimotuzumab Asian Scientific Meeting 2015

20th June, Afternoon (14:00-18:00)
ChairmenDr Normando E. Iznaga-EscobarTang
PingzhangLu Jiade
1. Nimotuzumab provides survival benefit to patients with
inoperable advanced squamous cell carcinoma of the head and
neck: A randomized, open-label, phase IIb, 5-year study in Indian
patients.
Dr Govind Babu, Kidwai Memorial Institute of Oncology,
Bangalore, India
2. An Investigator Initiated, Open Label, Multicentric, to evaluate
the Safety and Efficacy of Nimotuzumab (BIOMAb-EGFR) in
combination with concurrent Radiotherapy and Cisplatin versus
Radiotherapy and Cisplatin alone, in Subjects with Locally
advanced Squamous Cell Carcinoma of the Head and Neck
(LASCCHN) .
Dr Kumar Prabhash, Department of Medical Oncology, Tata
Memorial Hospital, Mumbai, Maharashtra, India.
3. Progress of maxillofacial and SCCHN tumors with EGFR
monoclonal antibody targeting treatment.
Guo Wei, The Ninths People Hospital Affiliated to Shanghai
Jiaotong University School of Medicine , Shanghai, China.
4. Multi-center phase II clinical trial of Nimotuzumab combined with
radiotherapy for locoregionally advanced nasopharyngeal.
Yi Junlin, Cancer Hospital Chinese Academy of Medical Science,
Beijing, China.
5. Study on serum CYFRA21-1value monitor of Nimotuzumab
combined sequent chemoradiotherapy in advanced
Nasopharyngeal carcinoma.
Song Xinmao, Eye &Ent Hospital of FUDAN Unviersity, Shanghai,
China.
6. An Open Label, Prospective, Multicentric Study to Evaluate the
2

Safety and Efficacy of BIOMAb-EGFRTM (Nimotuzumab) As

Induction and Maintenance Therapy in Combination with
Radiotherapy plus Temozolomide (Concomitant & Adjuvant) In
Indian Patients with Glioblastoma Multiforme.
Dr Radheshyam Naik, HCG Hospital, Bengaluru, Karnataka, India.
7. Nimotuzumab on the Treatment of malignant Glioma.
Wu Shaoxiong, Sun-Yat Sen University Cancer Center, Guangzhou,
China.
Discussion: Wang ShengziShi Mei
The Discussant: Dr Sunil GuptaDr Amish VohraZhu
XiaodongLin Qin

Nimotuzumab Asian Scientific Meeting 2015

21st June Morning (8:30-12:30)
Chairmen: Yu Jinming, Jiao Shunchang
Opening Remarks

Venue 1: Gastrointestinal Cancer Symposium

Session 1: Pancreatic cancer

Co-Chairs: Xu Jianming, Fu Deliang

1. Chinese Expert consensus on the Diagnosis and Treatment of
Pancreatic Cancer.
Dr Wang Liwei, Shanghai First People's Hospital, Shanghai, China
2. Incorporating Immunotherapy and Targeted Therapy in Pancreatic
Cancer. Dr Jiao Shunchang, The General Hospital of Peoples Liberation
Army (301 hospital), Beijing, China.
3. Progress of Treatment inPancreatic Cancer.
Dr Yuan Ying, The second affiliated hospital of zhejiang university,
China.
Discussion: Dr Hao Jihui
The Discussant: Dr Bai Yuxian, Dr Manish Singhal

TEA BREAK
Session 2: Esophageal cancer

Co-Chairs: Mao Weimin, Liang Jun, Yu Zhentao

1. First-line treatment of Esophageal Squamous Cells Carcinoma with
Nimotuzumab.
Dr Zhang Xiaodong, Tumor Hospital of Pekin University, Beijing, China
2. Treatment of malignant, non-resectable, epithelial origin esophageal
tumours with Nimotuzumab combined with Radiation Therapy and
Chemotherapy.
Dr Liang Jun, Tumor Hospital China Academy of Medical Sciences,
Beijing, China
3. NXCEL Trial: Randomized, Double-blind phase III study of Nimotuzumab
Plus chemoradiotherapy or Placebo Plus chemoradiotherapy in
Esophageal Squamous Cells Carcinoma.
Dr Meng Xue, The Tumor Hospital of Shandong Province, Shandong,
China.
4. Nimotuzumab in Combination with Chemoradiotherapy in case of
4

Locally Advanced Oesophageal Malignancy.

Dr ChanchalGowsami, B. P. Poddar Hospital & Medical Research
Limited, India.
Discussion: Dr Dai Guanghai
The Discussant: Dr Li Jiancheng, Dr J B Sharma
Concluding Remarks

Nimotuzumab Asian Scientific Meeting 2015

21st June Morning (8:30-12:30)
Venue 2, Head &Neck cancer Symposium
Session 1: Head and Neck Cancer
Co-Chairs: Lu TaixiangZhang Chenping
5

1.

2.

3.

4.

Opening Remarks
Therapeutic benefit of concurrent radiation with single agent
Nimotuzumab in locally advanced and recurrent HNSCC A
retrospective analysis.
Dr Anita Ramesh, SRMC, Porur, Chennai, India.
Clinical application of Nimotuzumab in hypopharyngeal carcinoma of
larynx preservation
Zhang Xinxin, Chinese PLA General Hospital, Beijing, China.
Clinical Research of Nimotuzumab plus cisplatin and paclitaxel
treatment in recurrence advanced metastatic head and neck cancer
Phase IIb Clinical Research
Dong Mei, Cancer Hospital Chinese Academy of Medical Science,Beijing
,China.
Clinical analysis of nimotuzumab plus cisplatin and fluorouracil regimen
as induction treatment in resectable head and neck squamous cell
carcinoma.
Zhao Xiaoying, Shanghai Cancer Center, Shanghai Medical School ,
Fudan University, Shanghai, China.
Discussion: Ge Minghua
The Discussant: Dr S SubramanianDr P S DattatreyaDr

NareshSomaniYang YipingHe XiaohuiLi Zhendong.

Concluding Remarks

TEA BREAK
Session 2: Nasopharyngeal Carcinoma
Co-Chairs: Pan JianjiHu Chaosu
Opening Remarks
1. Progress on Multimodality Therapy for Nasopharyngeal Car cinoma
Lin Shaojun, Fujian Province Cancer Hospital, Fuzhou, China.
2. Clinical Research of Nimotuzumab combined with chemoradiotherapy
on advanced Nasopharyngeal carcinoma
Chen Xiaozhong, Zhejiang Cancer Hospital, Hangzhou, China.
3. Radiotherapy combination with nimotuzumab on locally advanced NPC
after TPF neoadjuvant chemotherapy.
Kong Lin, Shanghai Proton Heavy Ion Hospital, Shanghai, China
Discussion: Hu Guoqing
The Discussant: Sun YanWang Ruozheng
Concluding Remarks

BIOMAb Experience Exchange Program

Program Details

Topic

Time (min)

Unmet needs in Head & Neck cancer An Asian perspective

Role of combined modality approaches with CT & biological
therapies in LASCCHN
Nimotuzumab clinical trial update
Nimotuzumab global update & clinical experience sharing
Clinical update on Singapore Phase III trial in Post-Op
Adjuvant setting in HNSCC
Clinical evidence of Nimotuzumab in Nasopharyngeal
carcinoma
Clinical evidence of Nimotuzumab in Pancreatic cancer
Real world Nimotuzumab cases Pancreatic cancer
Real world Nimotuzumab cases - Induction therapy in HNSCC
Real world Nimotuzumab cases -Esophageal cancer
Real world Nimotuzumab cases - Concurrent therapy in
HNSCC
Panel discussion

10.30 AM- 10.45 AM

10.45 AM- 11.05 AM
11.05 AM-11.25 AM
11.25 AM- 11.40 AM
11.40 AM- 11.50 AM
11.50 AM- 12.00 PM
12.00 PM- 12.10 PM
12.10 PM- 12.15 PM
12.15 PM- 12.20 PM
12.20 PM- 12.25 PM
12.25 PM-12.30 PM
12.30 PM- 1.00 PM

Venue : Beijing, China

Date : Saturday, June 20th 2015
Time : 10.30 AM 1 PM (followed by lunch)